There is a question I have been turning over for several years, ever since a close friend developed chronic back pain that no one could reliably explain or treat. She saw a primary care physician, an orthopedist, a neurologist, and a pain management specialist. She received an MRI, physical therapy, steroid injections, gabapentin, and eventually a referral for cognitive behavioral therapy. Nothing worked consistently. Nothing was wrong — at least, nothing any scan could identify. And yet the pain was relentless, debilitating, and entirely real.
Her experience is not unusual. It is, in fact, the norm for chronic pain in America. And the reason her care felt fragmented, contradictory, and ultimately inadequate is not that she had bad doctors. It is that chronic pain operates by rules that modern medicine was not designed to address.
The scale of the crisis
Chronic pain — defined as pain persisting for more than three months — affects an estimated 50.2 million American adults, or approximately 20.5% of the adult population, according to the most recent National Health Interview Survey data (Yong et al., 2022). This makes it more prevalent than diabetes (37.3 million), coronary heart disease (20.1 million), and cancer (18.1 million) combined.
The economic burden is equally staggering. The Institute of Medicine estimates that chronic pain costs the United States between $560 and $635 billion annually in direct medical costs and lost productivity — exceeding the combined costs of heart disease, cancer, and diabetes (Gaskin & Richard, 2012). By virtually any measure, chronic pain is the largest health crisis in America that most people cannot name.
Yet chronic pain receives a fraction of the research funding, clinical attention, and public health infrastructure devoted to conditions it dwarfs in prevalence. The National Institutes of Health allocates roughly $600 million annually to pain research — less than 2% of its total budget, and roughly one-tenth of what it spends on cancer research (NIH, 2023). Medical schools devote an average of 11 hours total to pain education across the entire four-year curriculum (Mezei & Murinson, 2011). Eleven hours to address a condition affecting one in five adults.
The paradigm problem
The fundamental challenge of chronic pain is that it violates the biomedical model that has guided Western medicine for centuries. In the traditional framework, pain is a symptom — a signal that tissue damage has occurred. Identify the damage, repair it, and the pain resolves. This model works brilliantly for acute pain: broken bones, surgical incisions, kidney stones. It fails catastrophically for chronic pain.
The reason is neurobiological. When pain persists beyond the normal healing window — typically 3-6 months — fundamental changes occur in the nervous system itself. Peripheral nerves become sensitized, transmitting pain signals at lower thresholds. Spinal cord neurons amplify those signals through a process called "wind-up." And the brain reorganizes its pain processing networks, creating self-sustaining pain circuits that persist long after the original tissue injury has healed — or in many cases, in the absence of any identifiable tissue injury at all.
This phenomenon — central sensitization — was first described by neuroscientist Clifford Woolf in 1983 and has since been validated by hundreds of studies using functional neuroimaging, quantitative sensory testing, and electrophysiology (Woolf, 2011). It is not controversial in pain science. But its implications remain poorly understood by most clinicians and almost entirely unknown to most patients.
Central sensitization means that chronic pain is not merely a prolonged version of acute pain. It is a different condition entirely — a disease of the nervous system rather than a symptom of tissue damage. This distinction has profound implications for treatment: strategies designed to address tissue pathology (surgery, injections, anti-inflammatory medications) often fail for centrally sensitized pain because they are solving the wrong problem.
The imaging paradox
One of the most counterintuitive findings in pain research is the weak correlation between structural findings on imaging and the actual experience of pain. A landmark study published in the New England Journal of Medicine performed MRI scans on 98 individuals with no history of back pain. The results were remarkable: 52% had at least one disc bulge, 27% had a disc protrusion, and 14% had an annular tear (Jensen et al., 1994). These are "abnormalities" that would almost certainly be identified as the cause of pain if the same individuals had presented with back complaints.
This finding has been replicated extensively. A meta-analysis of 3,110 asymptomatic individuals found that disc degeneration was present in 37% of 20-year-olds, 80% of 50-year-olds, and 96% of 80-year-olds (Brinjikji et al., 2015). These structural changes are not diseases. They are normal aging — the spinal equivalent of gray hair. Yet they are routinely identified as pain generators, leading to interventions ranging from injections to spinal fusion surgery that address anatomy but not the actual source of pain.
The opioid catastrophe
No discussion of chronic pain treatment in America can avoid the opioid crisis — both because it represents the most consequential failure of pain medicine in modern history and because its aftermath continues to distort how chronic pain is treated.
The story is well documented: beginning in the late 1990s, pharmaceutical companies aggressively marketed opioid analgesics for chronic non-cancer pain, supported by physician thought leaders who championed the concept of "pain as the fifth vital sign." Prescribing volumes quadrupled between 1999 and 2014. And the consequences were catastrophic: by 2021, opioid-related deaths exceeded 80,000 annually in the United States (CDC, 2022).
The pendulum has since swung dramatically. Opioid prescribing has declined by approximately 44% from its 2012 peak, driven by prescription drug monitoring programs, prescriber guidelines, and regulatory pressure (IQVIA, 2020). This reduction was necessary and overdue. But it has created a secondary crisis: patients with legitimate chronic pain conditions — including cancer survivors, individuals with sickle cell disease, and people with severe neuropathic conditions — now face enormous difficulty accessing medications that, for them, provide meaningful relief.
A survey published in Pain Medicine found that 53% of chronic pain patients reported difficulty obtaining prescribed opioid medications from pharmacies, and 42% reported that their physicians had involuntarily tapered or discontinued their opioid prescriptions in response to regulatory pressure rather than clinical assessment (Kroenke et al., 2019). The overcorrection has traded one harm for another.
What actually works
The evidence base for chronic pain treatment points consistently toward multimodal, interdisciplinary approaches rather than single-modality interventions. The most effective programs combine:
Exercise and movement therapy. A Cochrane review encompassing 264 studies found that exercise therapy produced clinically meaningful reductions in pain and disability for chronic low back pain, with effects comparable to or exceeding those of pharmacological interventions (Hayden et al., 2021). The mechanism is multifaceted: exercise reduces central sensitization, improves mood, enhances sleep, and rebuilds confidence in physical function.
Pain neuroscience education. Teaching patients about the neuroscience of chronic pain — specifically, how central sensitization creates pain in the absence of tissue damage — has been shown to reduce pain catastrophizing, improve function, and enhance the effectiveness of physical therapy. A meta-analysis found that pain neuroscience education produced moderate effect sizes for pain intensity, disability, and pain catastrophizing (Louw et al., 2016).
Psychological interventions. Cognitive behavioral therapy for chronic pain has the strongest evidence base of any psychological intervention, with a meta-analysis documenting significant improvements in pain intensity, disability, catastrophizing, and mood (Williams et al., 2012). Acceptance and commitment therapy (ACT) and mindfulness-based stress reduction (MBSR) have also demonstrated efficacy in well-designed trials.
Pharmacological management. When medications are appropriate, the evidence favors non-opioid approaches for most chronic pain conditions. Duloxetine and gabapentinoids have demonstrated efficacy for neuropathic pain and fibromyalgia. Low-dose naltrexone has shown promise for central sensitization conditions. And topical agents — lidocaine patches, capsaicin cream — can provide localized relief with minimal systemic effects.
The challenge is access. Comprehensive interdisciplinary pain programs produce the best outcomes but are scarce: the number of accredited pain rehabilitation programs in the United States has declined by over 50% since 1998 (Schatman, 2012). Insurance reimbursement for multimodal care remains inadequate. And the average wait time for a pain management appointment exceeds three months in most regions.
Moving forward
Chronic pain will not be solved by a single drug, device, or therapy. It will be addressed — incrementally, imperfectly — through a fundamental shift in how medicine conceptualizes and treats persistent pain: as a complex neurobiological condition requiring coordinated, patient-centered, multimodal care rather than a symptom to be suppressed.
That shift is underway, but it is slow. And in the meantime, tens of millions of Americans live with pain that their healthcare system is poorly equipped to treat. We can do better. The science tells us how. What we lack is not knowledge but will.
References
- Brinjikji, W., et al. (2015). Systematic literature review of imaging features of spinal degeneration in asymptomatic populations. AJNR, 36(4), 811–816.
- CDC. (2022). Drug Overdose Deaths in the U.S. Centers for Disease Control and Prevention.
- Gaskin, D. J., & Richard, P. (2012). The economic costs of pain in the United States. Journal of Pain, 13(8), 715–724.
- Hayden, J. A., et al. (2021). Exercise therapy for chronic low back pain. Cochrane Database, (9), CD009790.
- IQVIA. (2020). National Prescription Audit. IQVIA Institute.
- Jensen, M. C., et al. (1994). Magnetic resonance imaging of the lumbar spine in people without back pain. NEJM, 331(2), 69–73.
- Kroenke, K., et al. (2019). Challenges with implementing opioid guidelines. Pain Medicine, 20(5), 843–848.
- Louw, A., et al. (2016). The efficacy of pain neuroscience education on pain and disability. Physiotherapy Theory and Practice, 32(5), 332–355.
- Mezei, L., & Murinson, B. B. (2011). Pain education in North American medical schools. Journal of Pain, 12(12), 1199–1208.
- NIH. (2023). Estimates of Funding for Various Research, Condition, and Disease Categories. National Institutes of Health.
- Schatman, M. E. (2012). Interdisciplinary chronic pain management. Pain Medicine, 13(s1), S21–S34.
- Williams, A. C., et al. (2012). Psychological therapies for chronic pain in adults. Cochrane Database, (11), CD007407.
- Woolf, C. J. (2011). Central sensitization: Implications for the diagnosis and treatment of pain. Pain, 152(3), S2–S15.
- Yong, R. J., et al. (2022). Prevalence of chronic pain among adults in the United States. Pain, 163(2), e328–e332.